ClearFlow, Inc.’s PleuraFlow® Active Clearance Technology (ACT) System represents a significant innovation in post-cardiac surgery care. Designed to prevent chest tube clogging and ensure consistent evacuation of blood and fluids, the system addresses a critical challenge in recovery: retained blood syndrome (RBS). Unlike conventional drainage methods that are passive and prone to blockage, PleuraFlow enables active chest tube clearance at the bedside without breaking sterility. This innovation aligns directly with Enhanced Recovery After Surgery (ERAS) protocols, offering a proactive approach to improving surgical outcomes.

The technology was rigorously evaluated in a prospective clinical trial conducted at Franciscan Health Indianapolis, involving over 1,300 adult cardiac surgery patients. Compared to standard drainage, PleuraFlow significantly reduced complications, including a 41% reduction in retained blood syndrome and a 17% drop in postoperative atrial fibrillation (POAF). Importantly, it also shortened ICU stays by 30%, reduced ICU readmissions by 64%, and enabled earlier chest tube removal through a 23% reduction in total drainage volume. These benefits translate to faster recovery, fewer complications, and more efficient use of hospital resources.

The study’s results affirm the importance of integrating active chest tube clearance into routine cardiac surgery recovery protocols. With the ERAS Cardiac Society endorsing active chest tube maintenance as a Class I, Level B-NR recommendation, PleuraFlow stands out as a validated, effective tool that enhances both clinical outcomes and patient safety. As hospitals seek to optimize care and reduce costs, PleuraFlow offers a data-backed solution that improves recovery trajectories for cardiac surgery patients and empowers ICU teams with better control over postoperative management.

MedTech Spectrum's Summary

Proactive Postoperative Innovation : PleuraFlow® enables active chest tube clearance without breaking sterility, significantly reducing the risk of retained blood complications after cardiac surgery.

Clinically Proven Benefits : In a study of 1,334 patients, PleuraFlow® reduced retained blood syndrome by 41%, decreased POAF by 17%, and cut ICU time by 30%, supporting faster recovery and fewer readmissions.

ERAS-Aligned and Evidence-Based : Endorsed by the ERAS Cardiac Society, PleuraFlow® meets Class I, Level B-NR guidelines for active chest tube maintenance, making it a critical component of modern cardiac surgical care.